Cephalon, Inc. and BioAssets Development Corp. (BDC) have signed an agreement that will provide Cephalon with an option to acquire BDC. Cephalon will pay $30 million upfront and an additional payment if it exercises its option. BDC stockholders could also receive additional future payments related to regulatory and sales milestones. The agreement is subject to customary closing conditions. BDC, a privately held biopharmaceutical company, is currently conducting a Phase II placebo-controlled p...